This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Osi Pharmaceuticals, Inc.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations by Filippo Petti in Cancer Treatment
Introduction
Filippo Petti, a distinguished inventor based in Farmingdale, NY, has made significant contributions to the field of oncology through his innovative patent. With a focus on improving cancer treatment, his work aims to enhance the effectiveness of therapies involving epidermal growth factor receptor (EGFR) kinase inhibitors.
Latest Patents
Petti holds a notable patent titled "Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors." This patent provides groundbreaking diagnostic and prognostic methods for predicting how well a cancer patient may respond to treatment using EGFR kinase inhibitors. The invention describes methods to assess whether tumor cells have undergone an epithelial to mesenchymal transition (EMT), which influences their sensitivity to these inhibitors. By evaluating the expression levels of specific biomarkers, medical professionals can better predict treatment outcomes and improve therapeutic strategies for patients.
Career Highlights
Filippo Petti is currently affiliated with Osi Pharmaceuticals, Inc., where he continues to innovate within the pharmaceutical industry. His dedication to advancing cancer research has positioned him as a vital contributor to the development of new therapies that could significantly alter patient care in oncology.
Collaborations
Throughout his career, Petti has worked alongside esteemed colleagues, including John D. Haley and Stuart Thomson. Their collaborative efforts have fostered a rich environment of innovation, enabling them to explore new therapeutic avenues and enhance the impact of their research on cancer treatment.
Conclusion
In conclusion, Filippo Petti's inventive work represents a major step forward in understanding and treating cancer. His patent underscores the importance of biomarkers in evaluating treatment effectiveness and reveals potential pathways for improving patient outcomes. As research continues to evolve, contributions like Petti's will remain crucial in the fight against cancer.